MiNK Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $56.2M
- Price
- $11.01
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.59%
- Volume
- 5.9K
About
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
Quick stats
Shares outstanding5.1M
Computed float2.5M
Float / shares49.8%
Cash runway (months)9.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001840229
Websitehttps://minktherapeutics.com
AI Summary
AI-generated1/15
minorbullishclinical trial
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
MiNK Therapeutics will present two posters at the SITC 41st Annual Meeting in November 2026 covering tumor-cell killing in checkpoint inhibitor–resistant colorectal cancer liver metastases and elimination of senescent tumor cells and fibroblasts.
The first poster supports the rationale for the ongoing Phase 2 trial at Scripps, led by Darren Sigal, M.D., testing agenT-797 with botensilimab and balstilimab in previously treated MSS metastatic colorectal cancer with liver metastases (NCT07550088).
The second covers native agenT-797 and the FAP-targeting CAR-iNKT candidate MiNK-215 in preclinical models, highlighting complementary platform opportunities.